Overview

A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with Type 2 diabetes with fatty liver (>5.5% as measured with magnetic resonance imaging (MRI))
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Uppsala Clinical Research, Uppsala, Sweden
Treatments:
Dapagliflozin